CTKB
Cytek BiosciencesDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Faster instrument placements, higher consumables attach rates, and margin expansion drive durable revenue growth and multiple expansion, supporting a re‑rating toward the upper end of published analyst targets.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta -4.4.
What can break
Negative analyst revisions after quarterly results could trigger near-term share weakness.
Momentum
13
Value
41
Sentiment
89
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.73 · Bull $9.00 · Bear $3.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-01-29 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $6.00
Why
Momentum13 · Δ7d +1.0
Value41 · Δ7d +0.1
Sentiment89 · Δ7d -4.4
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
13
34% active weight
Current posture
7d trendFlat
Δ7d
+1.0
Δ21d
-22.2
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
89
33% active weight
Current posture
7d trendSoftening
Δ7d
-4.4
Δ21d
+6.0
Why this grade
Composite grade D. Momentum 12.5 / Value 41.1 / Sentiment 88.8
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$547.57M
Beta
1.30
Shares Out
127.86M
P/E (TTM) · Derived
-8.2
P/S (TTM)
3.38
P/FCF (TTM)
53.79
Rev YoY
+1.5%
EPS YoY
-705.8%
Gross Margin
+53.5%
Op Margin
-16.2%
Net Debt
-$272.15M
Current Ratio
5.17
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology